Search results for "Azoles"

showing 10 items of 899 documents

Psychophysical and electrofunctional contrast sensitivity in cataractous patients treated with bendazac-lysine salt

1990

The clinical progression of the cataract may be influenced by drugs which reduce the denaturation of lens proteins. One of the most promising drugs is the bendazac-lysine salt. The drug was used in a double-blind study of a group of patients with initial cortical cataract in order to evaluate the changes in visual acuity and contrast sensitivity by means of a psychophysical and an electrophysiological method. After 6 months of treatment with bendazac the mean values of visual acuity showed a statistically significant increase in respect to baseline values, as well as an improvement of the threshold of contrast for most spatial frequencies. In the eyes treated with placebo there was no stati…

medicine.medical_specialtyIndazolesVisual acuitygenetic structuresEye diseasemedia_common.quotation_subjectVisual AcuityPlaceboCataractContrast SensitivityLens proteinDouble-Blind MethodOral administrationPhysiology (medical)OphthalmologyBendazacPsychophysicsmedicineHumansContrast (vision)media_commonbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseeye diseasesSensory SystemsSurgeryElectrophysiologyOphthalmologyElectrophysiologyEvoked Potentials Visualmedicine.symptombusinessPhotic Stimulationmedicine.drugDocumenta Ophthalmologica
researchProduct

Effects of Long-Term Nitroglycerin Treatment on Endothelial Nitric Oxide Synthase (NOS III) Gene Expression, NOS III–Mediated Superoxide Production, …

2000

Abstract —Long-term nitroglycerin (NTG) treatment has been shown to be associated with cross-tolerance to endothelium-dependent vasodilators. It may involve increased production of reactive oxygen species (such as superoxide, O 2 ·− ) that rapidly inactivate the nitric oxide (NO) released from the endothelial cells. It remains to be elucidated, however, whether long-term treatment with NTG alters the activity and expression of the endothelial NO synthase (NOS III) and whether this enzyme can contribute to O 2 ·− formation. We studied the influence of long-term NTG treatment on the expression of NOS III as assessed by RNase protection assay and Western blot. Tolerance was measured ex vivo i…

medicine.medical_specialtyIndolesNitric Oxide Synthase Type IIIPhysiologyCarbazolesBiological AvailabilityVasodilationArginineNitric OxideGene Expression Regulation EnzymologicTimeNitric oxideNitroglycerinchemistry.chemical_compoundAlkaloidsSuperoxidesInternal medicinemedicineAnimalsRNA MessengerLucigeninCloning MolecularEnzyme InhibitorsRats WistarCalcimycinProtein Kinase CProtein kinase CBenzophenanthridineschemistry.chemical_classificationReactive oxygen speciesSuperoxideAcetylcholinePhenanthridinesRatsVasodilationEndocrinologychemistryBiochemistryEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular MedicineEx vivoAcetylcholinemedicine.drugCirculation Research
researchProduct

Spontaneous bisphosphonate-related osteonecrosis of the left hemi-mandible: Similarities with phossy jaw.

2013

Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term side effects BP, a form of avascular osteonecrosis of the jaw has been reported. Although, invasive oral local procedures are often present in clinical history of patients suffering from bisphosphonates-related osteonecrosis of the jaws (BRONJ), about up to 50% of BRONJ are spontaneous. We report a case of a 68-year-old female with a spontaneous wide bone sequestration of the left mandibular body onset after infusion of zoledronic acid for 18 cycles for osseous metastasis due to metastatic anaplastic thyroidal carcinoma. Surprisingly the clinical aspects of the patient initially reminded us …

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentBone NeoplasmsZoledronic AcidBone sequestrationstomatognathic systemMandibular bodySettore MED/28 - Malattie OdontostomatologichemedicineCarcinomaHumansMandibular DiseasesThyroid Neoplasmsthyroidal carcinomaGeneral DentistryAgedPhossy jawBone Density Conservation AgentsDiphosphonatesbusiness.industryCarcinomaMandibleImidazolesBisphosphonatesGeneral MedicineBisphosphonatemedicine.diseaseBisphosphonatesbisphosphonates‑related osteonecrosis of the jaws thyroidal carcinoma zoledronic acidbisphosphonates-related osteonecrosis of the jawsSurgerylcsh:RK1-715stomatognathic diseasesZoledronic acidlcsh:DentistryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugFollow-Up Studies
researchProduct

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting

2019

Real-life data confirming the favourable renal outcome in patients with heart failure (HF) treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We evaluated the renal effects of Sacubitril/Valsartan in a real-life sample of HF patients. Observational analysis of 54 consecutive outpatients affected by HF with reduced ejection fraction (HFrEF) and clinical indication for Sacubitril/Valsartan. Patients were evaluated at baseline (T0) and after six (T6) and twelve (T12) months after initiating Sacubitril/Valsartan and compared with a group of 30 historical controls. Mean age: 65.5 ± 11.7 years. Older patients: 29 (53.7%). Mean baseline estimated glomeru…

medicine.medical_specialtyMEDLINETetrazolesHeart failureLifeInternal MedicinemedicineHumansKidney dysfunctionSacubitril-ValsartanIntensive care medicinebusiness.industryAminobutyratesBiphenyl CompoundsFollow up studiesSacubitril/Valsartanmedicine.diseaseIm - OriginalDrug CombinationsValsartanHeart failureBlood pressureEmergency MedicineValsartanbusinessSacubitril ValsartanFollow-Up StudiesRenal functionmedicine.drug
researchProduct

Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain.

1996

Based on animal studies it has been reasoned that ligands to sigma binding sites might be effective in the treatment of schizophrenic disorders and may also be used to investigate this largely elusive disorder on a molecular level. Expression patterns of c-fos in rat brain were studied following treatment with single doses of the sigma ligand EMD 57445 (0.3, 1, 3, 30 mg/kg s.c.). Specific c-fos gene expression was detected at all concentrations tested in various cortical areas. The signals observed were dose-dependent with the highest intensities in the piriform cortex. Strong signals were also detected in hippocampal areas CA 1,2,3 and the gyrus dentatus, as well as in the medial habenula …

medicine.medical_specialtyMammillary bodyNucleus accumbensHippocampal formationc-FosHippocampusRats Sprague-DawleyPiperidinesPiriform cortexInternal medicinemedicineAnimalsReceptors sigmaPharmacology (medical)OxazolesBiological PsychiatryIn Situ HybridizationPharmacologybiologyDose-Response Relationship DrugChemistryOlfactory tubercleBrainRatsPsychiatry and Mental healthEndocrinologyNeurologyHypothalamusIslands of Callejabiology.proteinFemaleNeurology (clinical)Proto-Oncogene Proteins c-fosAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Bronchodilator and anti-inflammatory activities of SCA40: studies in human isolated bronchus, human eosinophils, and in the guinea-pig in vivo.

1998

There is currently interest in the use of inhibitors of cyclic nucleotide phosphodiesterases (PDE) as potential anti-asthma agents. In this study we examined the effects of SCA40 (6-bromo-8-methylaminoimidazol-[1,2-a] pyrazine-2-carbonitrile), a preferential inhibitor of PDE 3 also endowed with PDE 4 and 5 inhibitory activities, on isolated bronchus and eosinophil functions and in an animal model of asthma. SCA40 (1 nM-0.1 mM) produced concentration-dependent inhibition of spontaneous and stimulated tone of human isolated bronchus and reached a maximal relaxation similar to that of theophylline (3 mM). The potency (-log EC50 values) of SCA40 against spontaneous tone (6.52 +/- 0.10) was grea…

medicine.medical_specialtyMuscle RelaxationGuinea PigsBronchiIn Vitro Techniqueschemistry.chemical_compoundIn vivoInternal medicinemedicineAnimalsHumansTheophyllineAntigensRolipramPharmacologyLeukotrieneLeukotriene C4Anti-Inflammatory Agents Non-SteroidalImidazolesMuscle SmoothGeneral MedicineEosinophilLeukotriene C4Bronchodilator AgentsEosinophilsmedicine.anatomical_structureEndocrinologychemistryPyrazinesBronchoconstrictionmedicine.symptomBronchial HyperreactivityHistaminemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.

2015

A previous animal study compared the nephrotoxic effect of ibandronate (IBN) and zoledronate (ZOL), but interpretation of these study results was limited because of the model of minimal nephrotoxic dosage with a dosage ratio of 1:3. The present study investigated the nephrotoxicity of ibandronate and zoledronate in a 1.5:1 dose ratio, as used in clinical practice and compared the nephrotoxicity in rats with normal and with mildly to moderately impaired renal function. We compared rats with normal renal function (SHAM) and with impaired renal function after unilateral nephrectomy (UNX), treated either with ibandronate 1.5mg/kg, zoledronate 1mg/kg or placebo once (1×) or nine (9×) times. Rena…

medicine.medical_specialtyNecrosisMedullary cavitymedicine.medical_treatmentRenal functionPlaceboKidneyNephrectomyZoledronic AcidNephrotoxicityInternal medicinemedicineAnimalsHumansRenal InsufficiencyRats WistarIbandronic AcidPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesUnilateral nephrectomyBisphosphonateRatsEndocrinologyToxicityFemalemedicine.symptombusinessPharmacological research
researchProduct

Pantoprazole: from drug metabolism to clinical relevance.

2008

Conditions requiring inhibition of acid secretion, such as gastro-oesophageal reflux disease (GORD), peptic ulcers, non-ulcer dyspepsia or the use of NSAIDs, are very common, and their prevalence is expecting to rise as they are seen predominantly amongst the elderly. Among the drugs available to inhibit acid secretion, proton pump inhibitors (PPI) have been shown to have the best efficacy-safety ratio and have been used widely.This paper was intended to provide an overall presentation of one of these PPIs, pantoprazole.This study was first intended to give an overview of pantoprazole, so a Medline search was conducted using pantoprazole as unique search term, without publication date restr…

medicine.medical_specialtyPeptic UlcerPepticRabeprazoleLansoprazoleToxicologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesEsomeprazoleInternal medicinemedicineHumansPantoprazoleOmeprazolePantoprazolePharmacologyClinical Trials as Topicbiologybusiness.industryProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationAnti-Ulcer Agentsdigestive system diseasesTreatment OutcomeGastroesophageal RefluxbusinessDrug metabolismmedicine.drugExpert opinion on drug metabolismtoxicology
researchProduct

Edoxaban for pulmonary embolism with right ventricular dysfunction

2016

medicine.medical_specialtyPyridinesbusiness.industryVentricular Dysfunction RightVenous ThromboembolismHematology030204 cardiovascular system & hematologymedicine.diseaseRight ventricular dysfunctionPulmonary embolismThiazoles03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningchemistryEdoxabanInternal medicinemedicineCardiologyHumans030212 general & internal medicinePulmonary EmbolismbusinessThe Lancet Haematology
researchProduct

Iron Chelation Therapy in thalassaemia major: a sistematic review with meta-analyses of 1520 patients included on randomized clinical trials

2011

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using χ2 (Q) and I2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p<0.0001), increases in serum ferritin levels during DFX 5, 1…

medicine.medical_specialtyPyridonesIronMEDLINEThalassemiaSiderophoresDeferoxamineIron Chelating AgentsChelation treatment thalassaemia clinical trials iron overload meta-analysisBenzoatesGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansVentricular FunctionDeferiproneMolecular BiologyRandomized Controlled Trials as TopicEjection fractionbusiness.industryMyocardiumbeta-ThalassemiaDeferasiroxBeta thalassemiaCell BiologyHematologyTriazolesmedicine.diseaseChelation TherapySurgeryDeferoxamineDeferasiroxTreatment OutcomeLiverchemistryMeta-analysisFerritinsMolecular MedicineDrug Therapy CombinationbusinessDeferipronemedicine.drug
researchProduct